To reduce CLB side effects, Mahbub et al., disclosed a synergistic reduction in ATP and GSH levels, an increase in cell cycle arrest (in G2/M and/or S phases), DNA damage (an increase in γH2AX foci), and apoptosis (through activation of caspase pathways) in human lymphoid and myeloid leukemia cells by the combination therapy of apigenin with CLB [92]. Here, CLYBL is linked to myeloid leukemia.